StemCell Therapy

Biogen Announces Collaboration with University of Pennsylvania on Multiple Gene Therapy Programs

Biogen announced a broad collaboration and alliance with the University of Pennsylvania to advance gene therapy and gene editing technologies. The expansive research and translational development collaboration has multiple objectives, but will primarily focus on the development of therapeutic approaches that target the eye, skeletal muscle and the central nervous system. [Biogen] PressRelease

State Stem Cell Agency Awards Stanford Researchers

Albert Wong receives $2.9 million to develop vaccine for glioblastoma; four others awarded $240,000 each to study bladder, heart and eye conditions. [Stanford School of Medicine] PressRelease

MJFF Supports Stem Cell Projects to Explore Therapies and Provide Research Tools

The Michael J. Fox Foundation (MJFF) announced funding for two projects leveraging the promise of engineered stem cells to speed new therapies and deeper understanding of Parkinsons disease. [The Michael J. Fox Foundation] PressRelease

Novel Immunotherapy Trial for Lymphoma Offers Hope to Patients at Sylvester

Researchers are testing a novel cellular immunotherapy approach to treating patients with diffuse large B-cell lymphoma who have failed standard therapy. This investigational anti-CD19 chimeric antigen receptor T cell therapy, known as KTE-C19, is being studied in a Phase II clinical trial for patients with aggressive non-Hodgkins lymphoma. [University of Miami Miller School of Medicine] PressRelease

Asterias Biotherapeutics Announces Positive New Long-Term Follow-Up Results for AST-OPC1

Asterias Biotherapeutics, Inc. announced new positive long-term follow-up results from its Phase I clinical trial assessing the safety of AST-OPC1 (oligodendrocyte progenitor cells) in patients with spinal cord injury. [Asterias Biotherapeutics, Inc.] PressRelease

FDA Grants Roches Cancer Immunotherapy Tecentriq (Atezolizumab) Accelerated Approval for People with a Specific Type of Advanced Bladder Cancereneration CAR Modifications for Enhanced T-Cell Function

Roche announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval to Tecentriq for the treatment of people with locally advanced or metastatic urothelial carcinoma. [F. Hoffmann-La Roche Ltd.] PressRelease

Nano Dimension and Accellta Joined Forces to Successfully BioPrint Stem Cell-Derived Tissues

Nano Dimension Ltd. announced it has successfully lab-tested a proof of concept 3D Bioprinter for stem cells. The trial was conducted in collaboration with Accellta Ltd. [Nano Dimension Ltd. (PR Newswire Association LLC.)] PressRelease

Regen BioPharma, Inc. Announces ucVax: Universal Donor Cancer Cellular Immunotherapy

Regen BioPharma, Inc. and announced initiation of a preclinical development program aimed at creating the first cord blood based cancer immunotherapeutic product leveraging its NR2F6 immunological checkpoint. [Regen BioPharma, Inc. (PR Newswire Association LLC.)] PressRelease

VM BioPharma Announces FDA Fast Track Designation Granted for Investigational Gene Therapy VM202 for Patients with Amyotrophic Lateral Sclerosis (ALS)

VM BioPharma announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the companys lead investigational drug, VM202, a Phase II novel gene therapy for the potential treatment of Amyotrophic Lateral Sclerosis. [VM BioPharma] PressRelease

Cryoport to Provide Cold Chain Logistics Support for International Stem Cell Corporations Phase I Clinical Trial for the Treatment of Parkinsons Disease

Cryoport, Inc. announced that it will provide global logistics support to International Stem Cell Corporations (ISCO) Phase I clinical trial in Australia for the treatment of moderate to severe Parkinsons disease. ISCO commenced patient enrollment for the study earlier this month. [Cryoport, Inc.] PressRelease

WPI Team Awarded Patent for Reprograming Skin Cells

Cell therapies for a range of serious conditions, including heart attacks, diabetes, and traumatic injuries, will be accelerated by research at Worcester Polytechnic Institute (WPI) that yielded a newly patented method of converting human skin cells into engines of wound healing and tissue regeneration. [Worcester Polytechnic Institute] PressRelease

Caladrius Biosciences Licenses Cell Therapy Technology for Ovarian Cancer and Subleases Irvine Facility to AiVita Biomedical

Caladrius Biosciences, Inc. announces that it has licensed to AiVita Biomedical, Inc. the exclusive global rights to its tumor cell/dendritic cell technology for the treatment of ovarian cancer. [Caladrius Biosciences] PressRelease

Originally posted here:
Issues Archive - Cell Therapy News

This entry was posted on August 4, 2016 at 9:36 am and is filed under Cell Medicine. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |